SRRK vs MDGL vs AKRO vs ALNY

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 65. 2% for Alnylam Pharmaceuticals, Inc. (ALNY). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 127. 0x trailing P/E (44. 2x forward), making it the more compelling value choice. Analysts rate Scholar Rock Holding Corporation (SRRK) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +310. 1%, compared to +51. 4% for Scholar Rock Holding Corporation (SRRK). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus AKRO's +198. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.

(AKRO) is the lower-risk stock at 0. 35β versus Scholar Rock Holding Corporation's 1. 31β — meaning SRRK is approximately 276% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Akero Therapeutics, Inc. (AKRO) carries a lower debt/equity ratio of 5% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 65. 2% for Alnylam Pharmaceuticals, Inc. (ALNY). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -33. 2% for Scholar Rock Holding Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alnylam Pharmaceuticals, Inc.

(ALNY) is the more profitable company, earning 8. 4% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ALNY: 50.

6% to $445. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Akero Therapeutics, Inc.

(AKRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +198. 3% 10Y return). Both have compounded well over 10 years (AKRO: +198. 3%, SRRK: +199. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRRK is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; AKRO is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.